Global Injectable PrEP Market Strategic Research Report

Scope of the Report

The global Injectable PrEP market size is predicted to grow from US$ 301 million in 2025 to US$ 831 million in 2032; it is expected to grow at a CAGR of 15.8% from 2026 to 2032.

Injectable PrEP refers to HIV pre-exposure prophylaxis administered via parenteral routes—typically intramuscular or subcutaneous injection—most often in long-acting formulations that create a sustained-release “depot” and maintain protective drug exposure for weeks to months before potential HIV exposure occurs. The core problem it is designed to solve is the real-world implementation gap of oral PrEP: daily or event-driven pill-taking can be difficult to sustain due to adherence burden, refill continuity, privacy constraints, and stigma associated with visible medication use, and missed doses or interruptions can translate into gaps in protection. By shifting prevention from frequent self-managed dosing to periodic clinic- or program-based administration, injectable PrEP aims to improve continuity of coverage, reduce day-to-day behavioral load, and integrate more naturally with testing, follow-up, and broader sexual health services. Historically, injectable PrEP emerged after oral PrEP established efficacy and guidelines, leveraging advances from long-acting HIV treatment technologies—such as micro-/nano-crystal suspensions, stable depot formulations, and aseptic fill-finish—before expanding through regulatory approvals and phased rollout across regions, with service delivery models (visit cadence, workforce training, cold chain, and retention-in-care) becoming a central determinant of real-world uptake. Upstream, injectable PrEP depends on both conventional pharmaceutical inputs and a component-intensive aseptic supply chain: APIs and key intermediates; chemical reagents, solvents, and catalysts; injection-grade excipients (stabilizers, surfactants, buffers, water for injection, and formulation aids as needed); and the packaging/device components required for sterile manufacturing and administration (injectable-grade glass vials or prefilled syringes, elastomer stoppers/plungers, seals, needles and safety injection devices, sterilizing filters, single-use tubing and filling sets, labels, and cold-chain packaging), supported by specialized suppliers providing aseptic fill-finish capacity, sterilization validation, temperature-controlled logistics, and compliant quality systems.In 2025, the global production capacity of injectable PrEP reached 150,000 doses, while total sales amounted to 115,700 doses. The average selling price was USD 2,660 per dose, and manufacturers’ gross margins ranged between 60% and 70%.

Global key Injectable PrEP players cover Gilead Sciences, ViiV Healthcare, Aurobindo, Cipla, Viatris, etc.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Injectable PrEP market?

What factors are driving Injectable PrEP market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Injectable PrEP market opportunities vary by end market size?

How does Injectable PrEP break out by Type, by Application?

This report presents a comprehensive overview of the global Injectable PrEP market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Cabotegravir
• Lenacapavir
• Other

Segment by Dosing Interval

• Short-interval Injections
• Monthly Injections
• Quarterly Injections

Segment by Drug Properties

• Original Drug
• Generic Drug

Segment by Application

• Hospital
• Clinic
• Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Injectable PrEP market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Hospital, Clinic, Other evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact